Leukoreduction system chambers are a reliable cellular source for the manufacturing of T-cell therapeutics.

LRSCs are a reliable source of PBMCs for the generation of virus-specific T cells for immunotherapy. These findings have implications for the development of third-party therapeutic T-cell products from well-characterized blood product donors.